TEVA Teva Pharmaceutical Industries Limited

Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls

TCW Funds, an investment management firm, published its second-quarter 2026 investor letter for the “TCW Relative Value Mid Cap Fund”. The letter can be downloaded here. Equities advanced in Q2 2026, with the S&P 500 reaching record highs despite volatility from a Federal Reserve leadership transition and Middle East tensions. Markets rebounded from Q1 lows, […]

Wall Street analysts reshuffled their bets on energy giants, homebuilders, and emerging space plays on Thursday, and the moves cut in some surprising directions for names investors thought they had figured out.

UroGen's Zusduri sales surge, Jelmyto revenues and advancing pipeline assets strengthen its shift toward a commercial growth story.

Teva's branded drugs are driving stronger growth as Austedo, Ajovy and Uzedy gain momentum and its pipeline of new candidates expands.

Built on substance, not hype, Teva's mega rally is just getting started.

Teva Pharmaceutical (TEVA) is entering a strong growth phase despite near-term concerns around Auste

Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls

Teva Pharmaceutical Industries (NYSE:TEVA) is planning for greater financial flexibility after receiving investment-grade ratings from all three major credit rating agencies, President and CEO Richard Francis said at the BofA Global Healthcare Conference. Francis said the company achieved the miles

Teva Pharmaceutical Industries (NYSE:TEVA) Chief Executive Officer Richard Francis said the company has shifted from being viewed primarily as a generics manufacturer toward a biopharmaceutical company with a growing innovative medicines portfolio, while maintaining and expanding its generics operat

Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after its U.S. affiliate shared fresh Phase 3 SOLARIS data on investigational olanzapine LAI TEV-749 for adults with schizophrenia. The SOLARIS update follows a strong run for Teva Pharmaceutical Industries, with the share price at US$38.98 and a 7-day share price return of 5.35% building on an 18.7% year-to-date share price gain. A 3-year total shareholder return of about 2.8x and a 5-year total shareholder return of about 3.4x...

Options traders are targeting FPS, TEVA, and AFL

Teva Pharmaceutical Industries (NYSE:TEVA) CEO Richard Francis said the company has progressed from the initial phase of its “Pivot to Growth” plan into its next stage, citing momentum in branded medicines, innovation, generics and biosimilars, as well as improved financial flexibility. Speaking at

Teva Pharmaceuticals (TEVA) CEO Richard Francis joins Market Domination Overtime to discuss the company’s NYSE debut and what's next for the pharmaceutical company.

Teva Pharmaceutical Industries (NYSE:TEVA) said its “Pivot to Growth” strategy has moved into its second phase, with management pointing to momentum in branded medicines, a stabilized generics business, an expanding biosimilars portfolio and a strengthened balance sheet. Speaking at a Morgan Stanle

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has agreed to serve as the stalking-horse bidder for substantially all of BioXcel Therapeutics, Inc. (NASDAQ:BTAI)’s assets in a transaction valued at up to $125 million. The deal is structured as an upfront payment of $57.5 million followed by up to an additional $67.5 million in conditional milestone payments. Teva will […]

BridgeBio Pharma (BBIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Limited (NYSE:TEVA), agreed to serve as the stalking-horse bidder for substantially all assets of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) and certain affiliates through a court-supervised Chapter 11 auction. Teva Pharmaceutical Industries Limited (NYSE:TEVA) is the parent of the bidder and guarantor of the milestone-payment obligations. The […]

A historic bull signal is now flashing

Teva's TEV '408 meets its phase IIa celiac disease goal, preventing gluten-induced intestinal damage and showing a favorable safety profile.

President Donald Trump has secured new drug pricing agreements with nine pharmaceutical companies, with an aim to align the prices of drugs in the U.S. with international prices. The companies include Alcon Inc., Astellas Pharma, BeOne Medicines Ltd., BridgeBio, CSL,...

While Teva announced positive Phase II data, it has not yet confirmed Phase III plans.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) on Wednesday reported encouraging topline outcomes from an active Phase 2a clinical trial evaluating TEV ‘408, an experimental anti-interleukin-15 monoclonal antibody, for celiac disease. Coeliac disease is a chronic autoimmune condition where eating gluten damages the lining of the small intestine. The trial successfully achieved its primary goal, revealing that the investigational treatment significantly prevented intestinal damage caused by glut

Teva Pharmaceutical Industries (NYSE:TEVA) reported positive topline results from a Phase IIa gluten-challenge study of TEV-408, its anti-IL-15 antibody candidate for celiac disease, with the company saying the treatment met its primary endpoint and showed statistically significant effects on key me

JNJ faces Stelara and upcoming drug LOEs, MedTech weakness and talc litigation, but targets accelerated growth in 2026 and beyond.

Teva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.

Teva’s new Trailpeak trail running shoe, co-created with athletes in the Bureau of Adventure, gives Deckers Outdoor (DECK) fresh product news that could matter for investors watching its performance and specialty running exposure. Despite the Trailpeak launch and the recent expansion of its revolving credit facility, Deckers Outdoor’s share price has been under pressure, with a 30 day share price return down 12.7% and a 1 year total shareholder return down 31.2%. This signals fading momentum...

Trump's MFN push expands to nine mid-sized drugmakers, bringing 26 companies under agreements covering 89% of the branded drug market.

Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.

These deals will require the companies to provide MFN prices to state Medicaid programmes nationally.

Trump expanded his drug pricing deal to 26 pharma firms as UBS says healthcare stocks still have room to climb.

Under the deals, the drug makers would charge Americans no more than the lowest price paid in other rich countries.

The nine drug companies committed to collectively invest at least $19.6 billion in U.S. manufacturing in the near term.

The agreements provide for all state Medicaid programs to pay prices for prescription drugs that match the lowest prices paid by other developed nations, the White House said

The Trump administration has struck new drug pricing agreements with nine biotech and pharmaceutical companies including UCB SA, Bridgebio Pharma Inc. and Sun Pharmaceutical Industries Ltd.

TEVA's latest bid for BioXcel assets could expand its neuroscience portfolio with Igalmi and a potential at-home agitation treatment.

The transaction would see Teva obtain worldwide rights to Igalmi and the investigational BXCL501.

Teva Pharmaceutical Industries (NYSE:TEVA) agreed to acquire BioXcel Therapeutics' dexmedetomidine sublingual film for at-home treatment of agitation in schizophrenia and bipolar disorder through a bankruptcy asset sale process. The transaction is subject to approval by the bankruptcy court, potential competing bids, and standard closing conditions before Teva can assume full rights to the asset. The dexmedetomidine sublingual film is under FDA review for at-home use. This transaction is...

Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after the U.S. Food and Drug Administration accepted its New Drug Application for ecopipam, a first in class pediatric Tourette syndrome treatment. Despite the share price easing around 3% over the last day and 2% over the past week, Teva Pharmaceutical Industries has a 1 month share price return of about 4% and a year to date share price return of around 18%, while total shareholder return over the past year is close to 100%. This...

Teva Pharmaceutical Industries stock has delivered a very strong 284.4% gain over the past 5 years, yet current checks send mixed signals as the Discounted Cash Flow (DCF) estimate points to undervaluation while market based multiples screen the shares as expensive. Investors looking at Teva today see a stock with powerful recent momentum against a low overall value score that suggests it is not a straightforward bargain. A 284.4% return over 5 years highlights how much Teva has already...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) and Teva Pharmaceuticals Industries Limited (NYSE:TEVA) reached a major milestone on August 19, settling their U.S. patent dispute. Teva conceded that Aurinia’s patents covering its flagship oral lupus nephritis drug, LUPKYNIS, are valid, enforceable, and infringed by its proposed generic 7.9 mg voclosporin product. Teva agreed to delay generic commercialization until […]

BioXcel Therapeutics (BTAI) has entered into an agreement with Teva Pharmaceutical Industries (TEVA)

Deckers Outdoor has lagged the broader market over the past year, with analysts remaining cautiously optimistic about its future prospects.

Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.

Teva's ecopipam secures FDA priority review for pediatric Tourette syndrome, potentially bringing the first new therapy in over a decade.

AUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.

NBIX's Ingrezza sales climb 17% in 1H 2026 as strong volume drives a higher full-year outlook, but pricing risks loom.

Neurocrine's Q2 beat and higher Ingrezza guidance highlight strong growth, but rising spending and execution risks could test its expanding portfolio.

Neurocrine pairs rapid growth and expanding rare-disease assets with a premium sales valuation, making execution key to the investment case.

Alvotech (NASDAQ:ALVO) said its first-half 2026 results reflected a temporary manufacturing slowdown tied to facility and quality-system improvements at its Reykjavik site, while management reaffirmed full-year revenue and adjusted EBITDA guidance and highlighted upcoming regulatory decisions and pr